TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women With Polycystic Ovary Syndrome
Brief Summary: This research is to investigate the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-Ⅱ (AT-Ⅱ) to ovary stimulation during 24h in patients with polycystic ovary syndrome (PCOS).Controled prospective clinical study involved 60 women undergoing in vitro fertilization. Fifty-two patients with PCOS and 8 control cases were stimulated with human chorionic gonadotropin (HCG) during the early follicular phase of the menstrual cycle (4st to 7th days of the cycle).The blood was sampled before the injection (0 hour) and at the 3, 6, 12, 18 and 24 hours points after the stimulation. VEGF, AT-Ⅱ were measured by radioimmunoassay.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Intervention Type: DRUG; Name: Clomiphene citrate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): B
B: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: HCG | Intervention Type: DRUG; Name: HCG; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
D: Arm Label: Letrozole -Berberine; Type: EXPERIMENTAL; Interventions: Drug: Letrozole -Berberine | Arm Label: Letrozole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Arm Label: Berberine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Berberine | Intervention Type: DRUG; Name: Letrozole -Berberine; Assigned to Arm(s): Letrozole -Berberine | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): Letrozole | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.
Brief Summary: The purpose of this study is to determine whether pain treatment can reduce symptoms of depression in patients suffering from dementia and depression. Depression is commonly diagnosed in patients with dementia. If the investigators find a reduction in depressive symptoms when pain treatment is applied, this will support the hypothesis that undiagnosed pain may present itself as depression in patients with dementia.


Options:
A: Arm Label: Circadin; Type: EXPERIMENTAL; Interventions: Drug: Circadin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Circadin; Assigned to Arm(s): Circadin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Experimental: Tailored Music; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored music listening intervention | Arm Label: 4-week Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored music listening intervention; Assigned to Arm(s): Experimental: Tailored Music
C: Arm Label: AZD5213 doseA; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseB; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseC; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseA | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseB | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseC | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Paracetamol or buprenorphine treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol, Drug: Buprenorphine | Arm Label: Paracetamol placebo or buprenorphine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paracetamol placebo, Drug: Buprenorphine placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Paracetamol placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo | Intervention Type: DRUG; Name: Buprenorphine placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.
Brief Summary: The purpose of this study is to determine whether pain treatment can reduce symptoms of depression in patients suffering from dementia and depression. Depression is commonly diagnosed in patients with dementia. If the investigators find a reduction in depressive symptoms when pain treatment is applied, this will support the hypothesis that undiagnosed pain may present itself as depression in patients with dementia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2
B: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Buprenorphine plaster; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine plaster | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Buprenorphine plaster; Assigned to Arm(s): Buprenorphine plaster | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
C: Arm Label: Algorithm; Type: EXPERIMENTAL; Interventions: Behavioral: Algorithm | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Algorithm | Intervention Type: BEHAVIORAL; Name: Algorithm; Assigned to Arm(s): Algorithm, Control
D: Arm Label: Paracetamol or buprenorphine treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol, Drug: Buprenorphine | Arm Label: Paracetamol placebo or buprenorphine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paracetamol placebo, Drug: Buprenorphine placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Paracetamol placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo | Intervention Type: DRUG; Name: Buprenorphine placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.
Brief Summary: The purpose of this study is to determine whether pain treatment can reduce symptoms of depression in patients suffering from dementia and depression. Depression is commonly diagnosed in patients with dementia. If the investigators find a reduction in depressive symptoms when pain treatment is applied, this will support the hypothesis that undiagnosed pain may present itself as depression in patients with dementia.


Options:
A: Arm Label: Paracetamol or buprenorphine treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol, Drug: Buprenorphine | Arm Label: Paracetamol placebo or buprenorphine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paracetamol placebo, Drug: Buprenorphine placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Paracetamol placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo | Intervention Type: DRUG; Name: Buprenorphine placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo
B: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Suvorexant HD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant High Dose (HD) | Arm Label: Suvorexant LD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant Low Dose (LD) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Suvorexant High Dose (HD); Assigned to Arm(s): Suvorexant HD | Intervention Type: DRUG; Name: Suvorexant Low Dose (LD); Assigned to Arm(s): Suvorexant LD | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection
Brief Summary: The patients were randomized into 3 groups: those patients undergoing a ionic silver-containing dressing (ISD) (Group 1), those undergoing a Mupirocin ointment application (MOA) (Group 2) and those using a conventional dressing (Group 3) in the surgical wound after finishing an elective colorectal surgery.


Options:
A: Arm Label: I-ZIP Ocular Bandage; Type: EXPERIMENTAL; Interventions: Device: I-ZIP Ocular Bandage | Arm Label: Oasis 24 hour Soft Shield Collagen Corneal Shield; Type: ACTIVE_COMPARATOR; Interventions: Device: Oasis 24 Hour Soft Shield Collagen Corneal Shield | Intervention Type: DEVICE; Name: I-ZIP Ocular Bandage; Assigned to Arm(s): I-ZIP Ocular Bandage | Intervention Type: DEVICE; Name: Oasis 24 Hour Soft Shield Collagen Corneal Shield; Assigned to Arm(s): Oasis 24 hour Soft Shield Collagen Corneal Shield
B: Arm Label: ionic silver-containing dressing; Type: EXPERIMENTAL; Interventions: Procedure: ionic silver-containing dressing | Arm Label: Mupirocin ointment application; Type: EXPERIMENTAL; Interventions: Procedure: Mupirocin ointment application | Arm Label: Conventional dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: ionic silver-containing dressing; Assigned to Arm(s): ionic silver-containing dressing | Intervention Type: PROCEDURE; Name: Mupirocin ointment application; Assigned to Arm(s): Mupirocin ointment application
C: Arm Label: Mepore Self-adhesive absorbent dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Mepore Self-adhesive absorbent dressing | Arm Label: AQUAGEL Ag Hydrofiber Wound Dressing; Type: EXPERIMENTAL; Interventions: Device: AQUAGEL Ag Hydrofiber Wound Dressing | Intervention Type: DEVICE; Name: AQUAGEL Ag Hydrofiber Wound Dressing; Assigned to Arm(s): AQUAGEL Ag Hydrofiber Wound Dressing | Intervention Type: DEVICE; Name: Mepore Self-adhesive absorbent dressing; Assigned to Arm(s): Mepore Self-adhesive absorbent dressing
D: Arm Label: Silverlon Dressing; Type: EXPERIMENTAL; Interventions: Other: Silverlon | Arm Label: Standard of Care Dressing; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care Dressing | Intervention Type: OTHER; Name: Silverlon; Assigned to Arm(s): Silverlon Dressing | Intervention Type: OTHER; Name: Standard of Care Dressing; Assigned to Arm(s): Standard of Care Dressing

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer
Brief Summary: The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.


Options:
A: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
B: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
C: Arm Label: ONO-4538 Arm; Type: EXPERIMENTAL; Interventions: Drug: ONO-4538 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ONO-4538; Assigned to Arm(s): ONO-4538 Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: Physician choice chemotherapy+Best Supportive Care (BSC); Type: EXPERIMENTAL; Interventions: Drug: Irinotecan, Drug: Paclitaxel, Other: Best Supportive Care (BSC) | Arm Label: Avelumab+BSC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avelumab, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Avelumab; Assigned to Arm(s): Avelumab+BSC | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Physician choice chemotherapy+Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Physician choice chemotherapy+Best Supportive Care (BSC) | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Avelumab+BSC, Physician choice chemotherapy+Best Supportive Care (BSC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8 Week Randomized Controlled Trial Assessing Home Exercise Therapy in Early Cirrhosis
Brief Summary: Individuals with Cirrhosis have been shown to have a low aerobic capacity. While supervised exercise training has been shown to be an effective intervention to remedy this, there is currently no data on home based exercise interventions in this population. This study will evaluate the effects of a home based exercise program on the aerobic capacity of enrolled early stage liver cirrhosis patients, as well as changes in quality of life, thigh muscle thickness, and thigh muscle oxygen consumption.


Options:
A: Arm Label: Home based aerobic exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Home based Aerobic exercise training | Arm Label: Usual Care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home based Aerobic exercise training; Assigned to Arm(s): Home based aerobic exercise
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
C: Arm Label: Diet+Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Diet + exercise | Intervention Type: BEHAVIORAL; Name: Diet + exercise; Assigned to Arm(s): Diet+Exercise
D: Arm Label: Exercise + Leucine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Leucine supplements | Arm Label: Leucine without exercise; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Leucine supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Leucine supplements; Assigned to Arm(s): Exercise + Leucine, Leucine without exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Dexmedetomidine on the Incidence of Postoperative Delirium in Patients After Cardiac Surgery: a Randomized, Double-blinded, and Placebo-controlled Clinical Trial
Brief Summary: Postoperative delirium (POD) is a frequently occurring complication after cardiac surgery. Its occurrence is associated with worse outcomes of patients, including increased morbidity, prolonged hospital stay, increased medical cost, and higher mortality. It is also associated with long-term cognitive decline and decreased quality of life. However, until recently, pharmacological interventions that can effectively prevent its occurrence are still limited. The purpose of this study is to investigate whether perioperative dexmedetomidine use can decrease the incidence of postoperative delirium in patients undergoing cardiac surgery.


Options:
A: N/A
B: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
C: Arm Label: bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): bupivacaine, saline
D: Arm Label: Dex group; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine hydrochloride for injection | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride for injection | Intervention Type: DRUG; Name: dexmedetomidine hydrochloride for injection; Assigned to Arm(s): Dex group | Intervention Type: DRUG; Name: 0.9% sodium chloride for injection; Assigned to Arm(s): Placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment
Brief Summary: The purpose of the current study is to evaluate the effect of preimplantation genetic screening (PGS) by next generation sequencing (NGS) compared to standard morphological assessment of embryos on pregnancy rates through a randomized controlled trial (RCT). All embryos will be vitrified and a single embryo transfer (SET) will be performed with either screened or unscreened embryos depending on randomization.


Options:
A: Arm Label: Endometrial scratch group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endometrial scratch, Procedure: controlled ovarian hyperstimulation | Arm Label: Assisted hatching group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: assisted hatching, Procedure: controlled ovarian hyperstimulation | Arm Label: ovarian stimulation only group; Type: SHAM_COMPARATOR; Interventions: Procedure: controlled ovarian hyperstimulation | Intervention Type: PROCEDURE; Name: endometrial scratch; Assigned to Arm(s): Endometrial scratch group | Intervention Type: PROCEDURE; Name: assisted hatching; Assigned to Arm(s): Assisted hatching group | Intervention Type: PROCEDURE; Name: controlled ovarian hyperstimulation; Assigned to Arm(s): Assisted hatching group, Endometrial scratch group, ovarian stimulation only group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Preimplantation Genetic Screening by NGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Preimplantation Genetic Screening by NGS; Assigned to Arm(s): Group A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PIPELLE ENDOMETRIAL SAMPLING | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: PIPELLE ENDOMETRIAL SAMPLING; Assigned to Arm(s): 1
D: Arm Label: Control - Standard ART treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test - PGS; Type: EXPERIMENTAL; Interventions: Genetic: Next Generation Sequencing after Blastocyst biopsy | Intervention Type: GENETIC; Name: Next Generation Sequencing after Blastocyst biopsy; Assigned to Arm(s): Test - PGS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment
Brief Summary: The purpose of the current study is to evaluate the effect of preimplantation genetic screening (PGS) by next generation sequencing (NGS) compared to standard morphological assessment of embryos on pregnancy rates through a randomized controlled trial (RCT). All embryos will be vitrified and a single embryo transfer (SET) will be performed with either screened or unscreened embryos depending on randomization.


Options:
A: Arm Label: Single Embryo Transfer; Type: OTHER; Interventions: Other: Single Embryo Transfer | Arm Label: Double Embryo Transfer; Type: OTHER; Interventions: Other: Double embryo transfer | Intervention Type: OTHER; Name: Single Embryo Transfer; Assigned to Arm(s): Single Embryo Transfer | Intervention Type: OTHER; Name: Double embryo transfer; Assigned to Arm(s): Double Embryo Transfer
B: Arm Label: Control (no PGD); Type: N/A; Interventions: N/A | Arm Label: Case (PGD); Type: N/A; Interventions: N/A
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Preimplantation Genetic Screening by NGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Preimplantation Genetic Screening by NGS; Assigned to Arm(s): Group A
D: Arm Label: Polar Body Biopsy; Type: EXPERIMENTAL; Interventions: Other: Polar Body Biopsy | Arm Label: No Polar Body Biopsy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Polar Body Biopsy; Assigned to Arm(s): Polar Body Biopsy

Answer: C